pharmaceutical-sciences-2019-scientifictracks

8 / 11

allied
academies
Page 26
Notes:
July 05-06, 2019 | Paris, France
Pharmaceutics and Advanced Drug Delivery Systems
2nd International Conference and Exhibition on
Asian Journal of Biomedical and Pharmaceutical Sciences | ISSN:2249-622X | Volume 9
Exosomes: Growing interest as vectors of molecular entities
William Whitford
GE Healthcare, USA
Exosomes are a type of extracellular vesicle (EV) having
a unique generation pathway and characteristics. EVs
characteristics and cargo vary by the type and state of the
cells involved in their generation. They naturally carry such
diverse cargo as RNA, DNA, lipids, peptides and vast array of
proteins
Exosomes are produced by many types of cells and have been
discovered in nearly every bodily fluid. Their presence has
been reported in the growth medium of many cultured cells,
including B lymphocytes, dendritic cells, cytotoxic T-cells,
intestinalepithelialcells,neurons,oligodendrocytes,platelets,
mast cells, and Schwann cells. They have been demonstrated
to be active in immune response; neural communication;
reproduction and development; as well as in cell proliferation,
homeostasis andmaturation. Interest in exosomes is growing
due to the discovery of their potential in so many research,
diagnostic, analytic and therapeutic procedures.
Reasons for interest in exosomes include their observed
paracrine-like activity (replacing the communication
exhibited by their cells of origin) and their use as a vector of
proteins, nucleic acids or small-molecule drugs in therapeutic
applications. There are many approaches being pursued to
use exosomes as a vector of therapeutic agents. The primary
wayistoemployameansofdisruptionofthemembrane(such
as shear-forces) to allow passive diffusion of drug substance
into the exosome. Others describe their modification through
the fusion of exosomes with liposomes harboring desired
proteins, lipids or synthetic polymers. Some have even
proposed such creative manufacturing approaches as the in
vitro mass-production of exosome-mimicking nanovesicles
using a mini-extruder.
Codiak is a biotech start-up that has raised nearly $170million
toward development of exosomes in therapeutic applications.
They and others are manipulating exosomes to solve drug
delivery issues for small molecules, RNA therapies, proteins,
viral gene therapy, and even CRISPR gene-editing tools.
Speaker Biography
William Whitford is Strategic Solutions Leader, BioProcess, GE Healthcare,
USA with over 20 years’ experience in biotechnology product and process
development. He joined the company 16 years ago as a team leader in R&D
developing products supporting biomass expansion, protein expression
and virus secretion in mammalian and invertebrate cell lines. Products he
has commercialized include defined and animal product-free hybridoma
media, fed-batch supplements, and aqueous lipid dispersions. An invited
lecturer at international conferences, he has published over 250 articles,
book chapters and patents in several areas of bioproduction. He now
enjoys such industry activities as serving on the editorial advisory board for
BioProcess International.
e:
WilliamWhitford, Asian J Biomed Pharmaceut Sci, | ISSN: 2249-622X
Volume 9